Literature DB >> 21910725

In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis.

M Terčelj1, S Stopinšek, A Ihan, B Salobir, S Simčič, B Wraber, R Rylander.   

Abstract

Sarcoidosis is an inflammatory disease. Epidemiological and treatment studies suggest that fungi play a part in the pathogenesis. The aim of this work was to study the effect of fungal cell wall agents (FCWA) on the in vitro secretion of cytokines from peripheral blood monocytes from subjects with sarcoidosis and relate the results to fungal exposure at home and clinical findings. Subjects with sarcoidosis (n=22) and controls (n=20) participated. Peripheral blood mononuclear cells were stimulated with soluble or particulate β-glucan (S-glucan, P-glucan), chitin or lipopolysaccharide (LPS), whereafter tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-10 and IL-12 were measured. The severity of sarcoidosis was determined using a chest X-ray-based score. Serum cytokines (IL-2R, IL-6, IL-10 and IL-12) were determined. To measure domestic fungal exposure, air in the bedrooms was sampled on filters. N-acetylhexosaminidase (NAHA) on the filters was measured as a marker of fungal cell biomass. The induced secretion of cytokines was higher from peripheral blood mononuclear cells (PBMC) from subjects with sarcoidosis. P-glucan was more potent than S-glucan inducing a secretion. Chitin had a small effect. Among subjects with sarcoidosis there was a significant relation between the spontaneous PBMC production of IL-6, IL-10 and IL-12 and the NAHA levels at home. The P-glucan induced secretion of IL-12 was related to the duration of symptoms at the time of diagnosis. Their X-ray scores were related to an increased secretion of cytokines after stimulation with LPS or P-glucan. Subjects with sarcoidosis have a higher reactivity to FCWA in vitro and to home exposure. The influence of FCWA on inflammatory cells and their interference with the inflammatory defense mechanisms in terms of cytokine secretion could be important factors for the development of sarcoidosis.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910725      PMCID: PMC3193923          DOI: 10.1111/j.1365-2249.2011.04456.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  A case control etiologic study of sarcoidosis: environmental and occupational risk factors.

Authors:  Lee S Newman; Cecile S Rose; Eddy A Bresnitz; Milton D Rossman; Juliana Barnard; Margaret Frederick; Michael L Terrin; Steven E Weinberger; David R Moller; Geoffrey McLennan; Gary Hunninghake; Louis DePalo; Robert P Baughman; Michael C Iannuzzi; Marc A Judson; Genell L Knatterud; Bruce W Thompson; Alvin S Teirstein; Henry Yeager; Carol J Johns; David L Rabin; Benjamin A Rybicki; Reuben Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2004-09-03       Impact factor: 21.405

2.  Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers.

Authors:  H H Herfarth; S P Mohanty; H C Rath; S Tonkonogy; R B Sartor
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 3.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

4.  Antifungal treatment in sarcoidosis--a pilot intervention trial.

Authors:  Marjeta Tercelj; Tomaz Rott; Ragnar Rylander
Journal:  Respir Med       Date:  2006-09-18       Impact factor: 3.415

5.  Atopic status in patients with sarcoidosis.

Authors:  Nurdan Kokturk; Elif Reyhan Han; Haluk Turktas
Journal:  Allergy Asthma Proc       Date:  2005 Mar-Apr       Impact factor: 2.587

6.  Fungal cell wall agents suppress the innate inflammatory cytokine responses of human peripheral blood mononuclear cells challenged with lipopolysaccharide in vitro.

Authors:  Sanja Stopinšek; Alojz Ihan; Branka Wraber; Marjeta Terčelj; Barbara Salobir; Ragnar Rylander; Saša Simčič
Journal:  Int Immunopharmacol       Date:  2011-02-15       Impact factor: 4.932

7.  Interleukin-10 secretion by alveolar macrophages and monocytes in sarcoidosis.

Authors:  R Bingisser; R Speich; A Zollinger; E Russi; K Frei
Journal:  Respiration       Date:  2000       Impact factor: 3.580

8.  Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis.

Authors:  D R Moller; J D Forman; M C Liu; P W Noble; B M Greenlee; P Vyas; D A Holden; J M Forrester; A Lazarus; M Wysocka; G Trinchieri; C Karp
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

9.  Alveolar macrophages. V. Comparative studies on the antigen presentation activity of guinea-pig and rat alveolar macrophages.

Authors:  P G Holt; J E Batty
Journal:  Immunology       Date:  1980-10       Impact factor: 7.397

10.  Increased spontaneous interleukin-10 release from alveolar macrophages in active pulmonary sarcoidosis.

Authors:  Ute Oltmanns; Bernd Schmidt; Soeren Hoernig; Christian Witt; Matthias John
Journal:  Exp Lung Res       Date:  2003-07       Impact factor: 2.459

View more
  15 in total

Review 1.  Occupational causes of sarcoidosis.

Authors:  Kira L Newman; Lee S Newman
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

2.  β-glucan in the lymph nodes in sarcoidosis and in Kveim-Siltzbach test reagent.

Authors:  Marjeta Terčelj; Barbara Salobir; Ragnar Rylander
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis.

Authors:  George P Christophi; Tiffany Caza; Christopher Curtiss; Divya Gumber; Paul T Massa; Steve K Landas
Journal:  Exp Mol Pathol       Date:  2014-04-21       Impact factor: 3.362

4.  Human chitotriosidase: a sensitive biomarker of sarcoidosis.

Authors:  Elena Bargagli; David Bennett; Claudia Maggiorelli; Pasquale Di Sipio; Maria Margollicci; Nicola Bianchi; Paola Rottoli
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

Review 5.  Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.

Authors:  Amy S McKee; Shaikh M Atif; Michael T Falta; Andrew P Fontenot
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

6.  Fungal exposure and low levels of IL-10 in patients with sarcoidosis.

Authors:  Marjeta Terčelj; Sanja Stopinšek; Alojz Ihan; Barbara Salobir; Saša Simčič; Ragnar Rylander
Journal:  Pulm Med       Date:  2014-08-07

Review 7.  The Etiologic Role of Infectious Antigens in Sarcoidosis Pathogenesis.

Authors:  Lindsay J Celada; Charlene Hawkins; Wonder P Drake
Journal:  Clin Chest Med       Date:  2015-09-19       Impact factor: 2.878

8.  Fungal cell wall agents and bacterial lipopolysaccharide in organic dust as possible risk factors for pulmonary sarcoidosis.

Authors:  Sanja Stopinšek; Alojz Ihan; Barbara Salobir; Marjeta Terčelj; Saša Simčič
Journal:  J Occup Med Toxicol       Date:  2016-09-21       Impact factor: 2.646

Review 9.  The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.

Authors:  Rob J W Arts; Leo A B Joosten; Mihai G Netea
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

Review 10.  Environmental Risk Factors for Sarcoidosis.

Authors:  Marc A Judson
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.